pharmacogenetics: from dna to drug treatment andrew schork cogs 174 3/14/2012
TRANSCRIPT
![Page 1: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/1.jpg)
Pharmacogenetics:From DNA to Drug Treatment
Andrew SchorkCOGS 1743/14/2012
![Page 2: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/2.jpg)
“It is more important to know what sort of person has a disease than to know what sort of disease a person has.”
-Hippocrates (460 BC – 370 BC)
![Page 3: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/3.jpg)
• Pharmacogenomics– The science of how genes affect the way people people
respond to drugs– How genes affect…
…the way our body processes drugs (pharmacokinetics)…the interaction of drugs with receptors (pharmacodynamics)…the treatment efficacy and adverse side effects
• Pharmacogenetics– A subset of ‘pharmacogenomics’– The study of how inherited variation affects drug
response and metabolism
![Page 4: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/4.jpg)
Why is this a good approach?• Drugs can be dangerous– Many people have severe adverse reactions to drugs– Many people respond to drugs at different doses– Many drug treatments are horribly unpleasant, painful
• Drugs are expensive (to take and to make)– Ineffective drugs are a waste of money to take– Drug development needs to account for response
variability
• Genetics provide a priori information– Genetics don’t change (except in cancer)– Genetics can point to the cause not just the symptom
![Page 5: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/5.jpg)
![Page 6: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/6.jpg)
The waaay waaay back….• Pythagoras (the triangle guy)– Ancient Greek mathematician and
philosopher• Pythagoreanism (his belief system
and moral code) forbid eating and even touching of beans
• Reasons: ‘seed of life,’ looks like genitals, flatulence, damaging (Aristotle)
• Genetic glucose-6-phosphate dehydrogenase (G6PD) deficiency causes induced hemolytic anemia or ‘favism’
“…I ate his liver with some fava beans and a nice chianti”
![Page 7: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/7.jpg)
The waaaay back…• 1931 - DuPont chemist
Arthur Fox• PTC
(phenylthiocarbamide)• Lab accident led to the
discovery of ‘taste blindness’
• 1959 - Freidrich Vogel coined the term “pharmacogenetics” after discovering polymorphic enzymes
![Page 8: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/8.jpg)
Early studies…• Fast increase in awareness
of the interaction of drug and drug response
• Many family studies, twin studies and ‘top-down’ genetic studies
• Very laborious experimental work through the study enzyme actions and clinical observation
• PCR sped things up a bit
CYP2D6•1975 Smith and colleagues ingest a drug they are testing•He had a bad reaction but his colleagues did not•Family studies revealed genetic inheritance•Enzyme discovered and characterized•Enzyme cDNA sequenced and variants found (1990)•This family of gene important for many drugs
![Page 9: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/9.jpg)
The transition to the modern era…
• Human Genome Project and technological developments expanded the possibilities
![Page 10: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/10.jpg)
A brief aside into modern genetics
![Page 11: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/11.jpg)
SNPs
• Single Nucleotide Polymorphisms
• Most common and well studied form of variation
• Defined by a population frequency > 1%
![Page 12: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/12.jpg)
The Technology: Genotyping• Uses a microarray to measure a
limited predefined set of SNPs• Very high throughput (fast)• Very inexpensive (cheap)• Excellent coverage of common
variation (up to 5,000,000 SNPs)• Relies on Linkage Disequilibirum
A T C G A A A T G C A T G A C C T T T G A T A T G A T C G G C T G C A G T C A G CT T C G A A G T G C A T G A C T T T T G A C A T G A G C G G C G G C C C A C A G C
Microarray
Common Variation Rare Variation No Recorded Variation
![Page 13: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/13.jpg)
![Page 14: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/14.jpg)
Sequencer
A T C G A A A T G C A T G A C C T T T G A T A T G A T C G G C T G C A G T C A G CT T C G A A G T G C A T G A C T T T T G A C A T G A G C G G C G G C C C A C A G C
Common Variation Rare Variation No Recorded Variation
The Technology: Deep Sequencing• Captures every base pair in the
genome (3,000,000,000)• (Currently) low throughput (slow)• (Currently) Very expensive (> 10k)• Captures common, rare, and
personal variation• New and hard to analyze
![Page 15: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/15.jpg)
Back to the drugs…• The utility of pharmacogenetics:– Determining appropriate dosing– Avoiding unnecessary toxic treatments– Ensuring maximal efficacy– Reducing adverse side effects– Developing or choosing novel treatments– Can also explain variable response to illicit drugs
![Page 16: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/16.jpg)
Warfarin: A dosage story• Most widely used
anticoagulant in the world– A “blood thinner”
• Prescribed doses vary widely (1-40mg / daily)
• Therapuetic index is very low– High risk of bleeding early in
treatment
• Two genes involved in metabolism: CYP2C9 and VKORC1
![Page 17: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/17.jpg)
Homozygous wild-type CYP2C9 and VKORC1
Carrier of CYP2C9 mutant allele
Carrier of VKORC1 mutant allele
![Page 18: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/18.jpg)
CYP2C9 genotype Time to stable dose
*1/*1 extensive(normal) metabolizer 4 - 5 days
*1/*2 intermediate metabolizer 8 -10 days
*1/*3, *2/*2, *3/*3 intermediate or poor metabolizer 12-15 days
![Page 19: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/19.jpg)
Plavix: A story about effectiveness• Anti-clotting drug• Prescribed for coronary
artery disease and those who have suffered a heart attack or stroke or have a stent
• A “pro-drug”– Converted to active form
in the liver by CYP2C19
![Page 20: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/20.jpg)
CYP2C19 mutant carriers had reduced presence of the active ingredient (pharmacokinetics) and reduced ‘thinning’ (pharmacodynamics
![Page 21: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/21.jpg)
Pegasys: A toxic treatment story• Pegylated Interferon α-2a– Interferons are proteins
made in response to virus
• Treatment for Hepatitis B and C Virus
• Highly toxic treatment• Highly variable response,
especially in African Americans
• Very expensive
![Page 22: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/22.jpg)
![Page 23: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/23.jpg)
• One mutation in the IL28B gene (a natural interferon) increased efficacy two-fold
• This mutation is different in different ethnicities and explains half of the ethnic variability in treatment
![Page 24: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/24.jpg)
Cancer Treatments: A story about the future?
![Page 25: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/25.jpg)
Ozzy Osbourne: A story about different drugs
![Page 26: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/26.jpg)
Personalized Medicine• There is an emerging goal among ‘translational
scientists’ to make medical practice more personalized
• Pharmacogenetics isan important step towards that goal
• The effects of this movement are seen inmany aspects of society
![Page 27: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/27.jpg)
![Page 28: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/28.jpg)
Direct to consumer genetic testing• Companies now offer genetic testing services
directly to customers
• Pharmacogenetic testing is becoming an important aspect of this service
• Controversy about whether this should be available to anyone or only doctors and about its accuracy
• https://www.navigenics.com/member
![Page 29: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/29.jpg)
Economic investment is huge• Roche is a Swiss
pharmaceutical company
• Illumina is the world’s largest supplier of genome sequencing (San Diego based!)
• Interested in sequencing applications to drug development and diagnostics
http://money.howstuffworks.com/hostile-takeover.htm
![Page 30: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/30.jpg)
Concerns with this approach?• How reliable are the tests?• Are health care providers prepared to use this
information?• Will Insurance companies pay for the tests? • Will tailor made medicine lead to discrimination?• Will ethnic biases in science bias treatment
developments?
• Will this affect people’s privacy?
![Page 31: Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012](https://reader034.vdocuments.us/reader034/viewer/2022051618/56649cab5503460f9496cfa1/html5/thumbnails/31.jpg)